The Ebola Vaccine by Novavax Inc. has helped healthy people to develop an immune response against this deadly and popular virus in an early trial.
In a randomized study put in comparison against a placebo, the vaccine activated and brought about the immune system to build up antibodies as a measure of fighting ebola when combined with a supplement for increasing the production of the proteins to the maximum level, according to Gregg Glenn, who is the head of research at Novavax.
“We have a very, very robust immune response,” Glenn said by phone. Monkeys who exhibited the same response to the vaccine “were completely protected” from Ebola. Novavax presented a study about the effect of the vaccine on primates in March.
West Africa had to suffer a major breakout of the Ebola virus in early 2014, which caused the deaths of more than 11,000 people. And despite the fact that the spread of the virus has decreased greatly over time, there are some areas which are still affected, with 30 new confirmed cases in the week ended 12 July. Many potential vaccines from companies such as GlaxoSmithKline, Merck & Co. and NewLink Genetics, are being tested on humans.
The Novavax study also found that its vaccine was “well- tolerated” and safe, Glenn said, with minor side effects including headaches. The trial involved 230 healthy Australian adults.
Novavax also plans to create vaccines for respiratory syncytial virus, or RSV, and also influenzas and the Middle East Respiratory Syndrome coronavirus, according to its website. The headquarters of Novavax lies in Gaithersburg.